Interim report January 1 - March 31, 2012

The Board and President of Biolight AB (publ) hereby present the interim report for the first quarter 2012.

• Sales for the first quarter were SEK 1,987 thousand (1,843).

• Net operating loss for the first quarter was SEK -2,422 thousand (-2,099).

• Loss per share was SEK -0.04 (-0.08), and SEK -0.04 (-0.08) after full dilution.

• Agreement with Outdoor Tactical Inc. for distribution to the military sector in the USA, other NATO countries and allied countries

(For full report, see attached file)

OPERATIONS

Biolight is a medical technology company offering products based on the biological effects of dynamic, monochromatic light. Biolight provides a patented system for effective, painless and safe treatment of primarily wounds and other inflammatory conditions. The method accelerates the body’s own healing process and supplements traditional treatment. The treatment is non-pharmaceutical and is applied externally. It prevents inflammatory injuries, contributes to enhanced quality of life, reduces recovery time after physical exertion, as well as reduces healing times and treatment costs.

We offer user-friendly, hand-held treatment equipment to both patients and caregivers in human and veterinary medicine for applying the method. The company’s revenue is generated through rental or sales of treatment equipment as well as sales of treatments that are downloaded to the equipment.

Biolight mainly focuses on two application areas: treatment of slow-healing wounds in medical and geriatric care and injuries in equestrian sports. The Biolight share is listed on the Nordic MTF (Nordic Growth Market AB).

Further information:

For further information, please contact Pär Olausson Lidö, President, tel: +46 8 753 70 89, or +46 702 15 01 11.

Biolight AB (publ) is a medical technology company offering solutions to care providers based on the Company’s patented method for using pulsating monochromatic light. The Company’s method reduces healing times and treatment costs. Over the last couple of years, Biolight has focused on a small number of application areas, primarily treatment of slow-healing wounds and injuries. The Biolight share is listed on the Nordic MTF (Nordic Growth Market AB).